These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 37398252)
1. Estimating post-treatment recurrence after multidrug-resistant tuberculosis treatment among patients with and without HIV: the impact of assumptions about death and missing follow-up. Sauer SM; Mitnick CD; Khan U; Hewison C; Bastard M; Holtzman D; Law S; Khan M; Padayachee S; Ahmed S; Isani AK; Krisnanda A; Vilbrun SC; Bektasov S; Kumsa A; Docteur W; Tintaya K; McNicol M; Atshemyan H; Voynilo T; Thwe TT; Seung K; Rich M; Huerga H; Khan P; Franke M medRxiv; 2023 May; ():. PubMed ID: 37398252 [TBL] [Abstract][Full Text] [Related]
2. Estimating Post-treatment Recurrence After Multidrug-Resistant Tuberculosis Treatment Among Patients With and Without Human Immunodeficiency Virus: The Impact of Assumptions About Death and Missing Follow-up. Sauer SM; Mitnick CD; Khan U; Hewison C; Bastard M; Holtzman D; Law S; Khan M; Padayachee S; Ahmed S; Isani AK; Krisnanda A; Vilbrun SC; Bektasov S; Kumsa A; Docteur W; Tintaya K; McNicol M; Atshemyan H; Voynilo T; Thwe TT; Seung K; Rich M; Huerga H; Khan P; Franke M Clin Infect Dis; 2024 Jan; 78(1):164-171. PubMed ID: 37773767 [TBL] [Abstract][Full Text] [Related]
3. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas. Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557 [TBL] [Abstract][Full Text] [Related]
4. Bedaquiline safety, efficacy, utilization and emergence of resistance following treatment of multidrug-resistant tuberculosis patients in South Africa: a retrospective cohort analysis. Pai H; Ndjeka N; Mbuagbaw L; Kaniga K; Birmingham E; Mao G; Alquier L; Davis K; Bodard A; Williams A; Van Tongel M; Thoret-Bauchet F; Omar SV; Bakare N BMC Infect Dis; 2022 Nov; 22(1):870. PubMed ID: 36414938 [TBL] [Abstract][Full Text] [Related]
5. Treatment outcomes 24 months after initiating short, all-oral bedaquiline-containing or injectable-containing rifampicin-resistant tuberculosis treatment regimens in South Africa: a retrospective cohort study. Ndjeka N; Campbell JR; Meintjes G; Maartens G; Schaaf HS; Hughes J; Padanilam X; Reuter A; Romero R; Ismail F; Enwerem M; Ferreira H; Conradie F; Naidoo K; Menzies D Lancet Infect Dis; 2022 Jul; 22(7):1042-1051. PubMed ID: 35512718 [TBL] [Abstract][Full Text] [Related]
6. Effectiveness and cardiovascular safety of delamanid-containing regimens in adults with multidrug-resistant or extensively drug-resistant tuberculosis: A nationwide cohort study from Belarus, 2016-18. Auchynka V; Kumar AMV; Hurevich H; Sereda Y; Solodovnikova V; Katovich D; Setkina S; Yedilbayev A; Skrahin A; Skrahina A Monaldi Arch Chest Dis; 2021 Jan; 91(1):. PubMed ID: 33470081 [TBL] [Abstract][Full Text] [Related]
7. Six-month therapy for abdominal tuberculosis. Jullien S; Jain S; Ryan H; Ahuja V Cochrane Database Syst Rev; 2016 Nov; 11(11):CD012163. PubMed ID: 27801499 [TBL] [Abstract][Full Text] [Related]
8. Comparative effectiveness of adding delamanid to a multidrug-resistant tuberculosis regimen comprised of three drugs likely to be effective. Rodriguez CA; Lodi S; Horsburgh CR; Mitnick CD; Bastard M; Huerga H; Khan U; Rich M; Seung KJ; Atwood S; Manzur-Ul-Alam M; Melikyan N; Mpinda S; Myint Z; Naidoo Y; Petrosyan O; Salahuddin N; Sarfaraz S; Vilbrun SC; Yae K; Achar J; Ahmed S; Algozhina E; Beauchamp J; de Guadelupe Perea Moreno S; Gulanbaeva M; Gergedava M; Indah Sari CY; Hewison C; Khan P; Franke MF PLOS Glob Public Health; 2023; 3(4):e0000818. PubMed ID: 37115740 [TBL] [Abstract][Full Text] [Related]
9. Comparative safety of bedaquiline and delamanid in patients with multidrug resistant tuberculosis: A nationwide retrospective cohort study. Kim JH; Lee H; Oh IS; Jeong HE; Bea S; Jang SH; Son H; Shin JY J Microbiol Immunol Infect; 2023 Aug; 56(4):842-852. PubMed ID: 37202241 [TBL] [Abstract][Full Text] [Related]
10. Evaluating newly approved drugs for multidrug-resistant tuberculosis (endTB): study protocol for an adaptive, multi-country randomized controlled trial. Guglielmetti L; Ardizzoni E; Atger M; Baudin E; Berikova E; Bonnet M; Chang E; Cloez S; Coit JM; Cox V; de Jong BC; Delifer C; Do JM; Tozzi DDS; Ducher V; Ferlazzo G; Gouillou M; Khan A; Khan U; Lachenal N; LaHood AN; Lecca L; Mazmanian M; McIlleron H; Moschioni M; O'Brien K; Okunbor O; Oyewusi L; Panda S; Patil SB; Phillips PPJ; Pichon L; Rupasinghe P; Rich ML; Saluhuddin N; Seung KJ; Tamirat M; Trippa L; Cellamare M; Velásquez GE; Wasserman S; Zimetbaum PJ; Varaine F; Mitnick CD Trials; 2021 Sep; 22(1):651. PubMed ID: 34563240 [TBL] [Abstract][Full Text] [Related]
11. Culture Conversion in Patients Treated with Bedaquiline and/or Delamanid. A Prospective Multicountry Study. Franke MF; Khan P; Hewison C; Khan U; Huerga H; Seung KJ; Rich ML; Zarli K; Samieva N; Oyewusi L; Nair P; Mudassar M; Melikyan N; Lenggogeni P; Lecca L; Kumsa A; Khan M; Islam S; Hussein K; Docteur W; Chumburidze N; Berikova E; Atshemyan H; Atwood S; Alam M; Ahmed S; Bastard M; Mitnick CD Am J Respir Crit Care Med; 2021 Jan; 203(1):111-119. PubMed ID: 32706644 [No Abstract] [Full Text] [Related]
12. Incremental Cost Effectiveness of Bedaquiline for the Treatment of Rifampicin-Resistant Tuberculosis in South Africa: Model-Based Analysis. Schnippel K; Firnhaber C; Conradie F; Ndjeka N; Sinanovic E Appl Health Econ Health Policy; 2018 Feb; 16(1):43-54. PubMed ID: 28980217 [TBL] [Abstract][Full Text] [Related]
13. Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB. Sharma SK; Sharma A; Kadhiravan T; Tharyan P Evid Based Child Health; 2014 Mar; 9(1):169-294. PubMed ID: 25404581 [TBL] [Abstract][Full Text] [Related]
14. Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB. Sharma SK; Sharma A; Kadhiravan T; Tharyan P Cochrane Database Syst Rev; 2013 Jul; 2013(7):CD007545. PubMed ID: 23828580 [TBL] [Abstract][Full Text] [Related]
15. Cost comparison of nine-month treatment regimens with 20-month standardized care for the treatment of rifampicin-resistant/multi-drug resistant tuberculosis in Nigeria. Bada FO; Blok N; Okpokoro E; Dutt S; Akolo C; Dakum P; Abimiku A PLoS One; 2020; 15(12):e0241065. PubMed ID: 33259492 [TBL] [Abstract][Full Text] [Related]
16. Linezolid for drug-resistant pulmonary tuberculosis. Singh B; Cocker D; Ryan H; Sloan DJ Cochrane Database Syst Rev; 2019 Mar; 3(3):CD012836. PubMed ID: 30893466 [TBL] [Abstract][Full Text] [Related]
17. Treatment and outcomes in children with multidrug-resistant tuberculosis: A systematic review and individual patient data meta-analysis. Harausz EP; Garcia-Prats AJ; Law S; Schaaf HS; Kredo T; Seddon JA; Menzies D; Turkova A; Achar J; Amanullah F; Barry P; Becerra M; Chan ED; Chan PC; Ioana Chiotan D; Crossa A; Drobac PC; Fairlie L; Falzon D; Flood J; Gegia M; Hicks RM; Isaakidis P; Kadri SM; Kampmann B; Madhi SA; Marais E; Mariandyshev A; Méndez-Echevarría A; Moore BK; Nargiza P; Ozere I; Padayatchi N; Ur-Rehman S; Rybak N; Santiago-Garcia B; Shah NS; Sharma S; Shim TS; Skrahina A; Soriano-Arandes A; van den Boom M; van der Werf MJ; van der Werf TS; Williams B; Yablokova E; Yim JJ; Furin J; Hesseling AC; PLoS Med; 2018 Jul; 15(7):e1002591. PubMed ID: 29995958 [TBL] [Abstract][Full Text] [Related]
18. Principles of chemotherapy for tuberculosis in national tuberculosis programmes of low- and middle-income countries. Chiang CY; Lin CJ Indian J Tuberc; 2020 Dec; 67(4S):S16-S22. PubMed ID: 33308663 [TBL] [Abstract][Full Text] [Related]
19. Injectable-free regimens containing bedaquiline, delamanid, or both for adolescents with rifampicin-resistant tuberculosis in Khayelitsha, South Africa. Mohr-Holland E; Reuter A; Furin J; Garcia-Prats A; De Azevedo V; Mudaly V; Kock Y; Trivino-Duran L; Isaakidis P; Hughes J EClinicalMedicine; 2020 Mar; 20():100290. PubMed ID: 32154506 [TBL] [Abstract][Full Text] [Related]